The cost-effectiveness of paliperidone extended release in Spain

Journal of Medical Economics

Volumn 15, Issue SUPPL. 1, 2012, Pages 26-34

  Treur, M ^a   Baca, E ^b   Bobes, J ^c   Canas F ^d   Salvador, L ^e   Gonzalez, B ^f   Heeg, B ^a  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

^d Hospital Dr Rodríguez Lafora   (Spain)

^e Fundacion Villablanca   (Spain)

^f Health Economics Department   (Spain)

Author keywords

Cost effectiveness; Discrete even simulation; Paliperidone ER; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG RELEASE; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; INTERVIEW; LENGTH OF STAY; PATIENT COMPLIANCE; PROBABILITY; QUALITY OF LIFE; RELAPSE; SCHIZOPHRENIA; SEDATION; SENSITIVITY ANALYSIS; SIDE EFFECT; SIMULATION; SOMNOLENCE; SPAIN; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; HUMANS; ISOXAZOLES; PYRIMIDINES; QUALITATIVE RESEARCH; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA; SPAIN;

EID: 84869408874     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.734884     Document Type: Article

References (51)

1. Eusko Jaurlaritza Gobierno Vasco. Informe aná lisis de impacto presupuestario Paliperidona. Departamento de Sanidad GV 2009.
2. Oliva-Moreno J, Lopez-Bastida J, Osuna-Guerrero R, et al. The costs of schizophrenia in Spain. Eur J Health Econ 2006;7:182-8
3. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008;16:31-43
4. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-29
5. Canuso CM, Youssef EA, Bossie CA, et al. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008;23:209-15
6. Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebocontrolled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009;166:691-701
7. National Collaborating Centre for Mental Health, National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (Update), Chapter 7.2. 2009 http://www.ncbi.nlm.nih.gov/books/NBK11681/pdf/TOC. pdf. Accessed October 16, 2012
8. Heeg BMS, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005;23:17-33
9. Laux G, Heeg BMS, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23:49-61
10. Chue PS, Heeg BMS, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23:62-74
11. Hensen M, Heeg B, Lothgren M, et al. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy 2010;8:327-41
12. Larsen TK, Moe LC, Vibe-Hansen L, et al. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000;29:1-9
13. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6
14. Lindenmayer JP, Czobor P, Volavka J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004;65:551-6
15. Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006;51:531-9
16. Mahmoud R, Engelhart L, Janagap C, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder; symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004;24:275-86
17. Lenert L, Sturley A, Rapaport M, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:155-65
18. Zhou H, Isaman DJM, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28:2856-63
19. Landy J, Stein J, Brown MM, et al. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit 2002;8:CR543-8
20. Siddique R, Markowitz J, Engelhart L. Impact of atypical antipsychotic drug sedation on quality of life. Atlanta, Georgia: American Psychiatric Assocociation, 2005.
21. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperisone on risk of diabetes among patients with schizophreia: population based nested case-control study. BMJ 2002;325:243
22. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25
23. Johnson & Johnson Pharmaceutical Research. Extended Release OROS Paliperidone in the Treatment of Schizophrenia. Module 2.5-Clinical Overview. R076477. New Brunswick, New Jersey, USA: Johnson & Johnson Pharmaceutical Research, 2006.
24. Johnson & Johnson Pharmaceutical Research. Extended Release OROS Paliperidone in the Treatment of Schizophrenia. Module 2.7.3-Summary of Clinical Evidence. New Brunswick, New Jersey, USA: Johnson & Johnson Pharmaceutical Research, 2005.
25. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63
26. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-404
27. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
28. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
29. Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005;2:CD005237
30. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;2:CD000967
31. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;2:CD004578
32. Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000;4:CD001945
33. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000059
34. THieda P, Beard S, Richter A, et al. An economic review of compliance therapy with medication in the treatment of schizophrenia. Psych Serv 2003;54:508-16
35. Dolder C, Lacro J, Dunn L, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8
36. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
37. Schooler N, Rabinowitz J, Davidson M, et al. Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162:947-53
38. Leucht S, Barnes T, Kissling W, et al. Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory metaanalysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22
39. Fleischhacker W, Oehl M, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64:S3-S9
40. Remington G, Adams M. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40:S5-S11
41. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995;9(Suppl 5):17-20
42. Vazquez-Polo FJ, Negrin M, Cabases JM, et al. An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. J Ment Health Policy Econ 2005;8:153-65
43. Boletin Oficial de Murcia. 2009
44. Geitona M, Kousoulakou H, Ollandezos M, et al. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Ann Gen Psychiatry 2008;7:16
45. Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008;24:3341-55
46. Janicak PG, Wu JH, Mao L. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials. Curr Med Res Opin 2008;24:1807-15
47. Wieck A, Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. BMJ 2002;324:250-2
48. Bobes J, Garcia-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003;29:125-47
49. Ucok A, Incesu C, Aker T, et al. Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 2007;22(5):328-33. Epub 2007 Mar 6
50. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
51. Mason P, Harrison G, Glazebrook C, et al. The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISos) coordinated by the World Health Organisation. Br J Psychiatry 1996;169:580-6